As­traZeneca R&D leader Pan­ga­los warns of a post-Brex­it UK re­search re­treat with­out re­im­burse­ment re­form

As­traZeneca’s in­flu­en­tial R&D leader Mene Pan­ga­los has blast­ed the UK gov­ern­ment’s drug watch­dog NICE for keep­ing the price of new drugs at low lev­els, say­ing that reg­u­la­tors are threat­en­ing the in­dus­try’s sub­stan­tial R&D pres­ence in the coun­try in a post-Brex­it world.

“To con­tin­ue to get the re­search and in­vest­ment here, you have to pay for the drugs,” Pan­ga­los told The Tele­graph in an in­ter­view. “Re­search and adop­tion of clin­i­cal in­no­va­tion go hand in hand and the Gov­ern­ment has to be pre­pared to pay for treat­ments that work.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.